In August 2021, the Californian company was acquired by Bayer, and is now an independently operated subsidiary.

Vividion is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. The company's lead programs target NRF2, STAT3 and WRN.